GUILLAIN-BARRE SYNDROME FOLLOWING VACCINATION IN THE NATIONAL INFLUENZA IMMUNIZATION PROGRAM, UNITED STATES, 1976–1977

Because of an increase in the number of reports of Guillain-Barre syndrome (GBS) following A/New Jersey influenza vaccination, the National Influenza Immunization Program was suspended December 16, 1976 and nationwide surveillance for GBS was begun. This surveillance uncovered a total of 1098 patien...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of epidemiology 1979-08, Vol.110 (2), p.105-123
Hauptverfasser: SCHONBERGER, LAWRENCE B., BREGMAN, DENNIS J., SULLIVAN-BOLYAI, JOHN Z, KEENLYSIDE, RICHARD A., ZIEGLER, DONALD W., RETAILLIAU, HENRY F., EDDINS, DONALD L, BRYAN, JOHN A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Because of an increase in the number of reports of Guillain-Barre syndrome (GBS) following A/New Jersey influenza vaccination, the National Influenza Immunization Program was suspended December 16, 1976 and nationwide surveillance for GBS was begun. This surveillance uncovered a total of 1098 patients with onset of GBS from October 1, 1976, to January 31, 1977, from all 50 states, District of Columbia, and Puerto Rico. A total of 532 patients had recently received an A/New Jersey influenza vaccination prior to their onset of GBS (vaccinated cases), and 15 patients received a vaccination after their onset of GBS. Five hundred forty-three patients had not been recently vaccinated with A/New Jersey influenza vaccine and the vaccination status for 8 was unknown. Epidemiologic evidence indicated that many cases of GBS were related to vaccination. When compared to the unvaccinated population, the vaccinated population had a significantly elevated attack rate in every adult age group. The estimated attributable risk of vaccine-related GBS in the adult population was just under one case per 100,000 vaccinations. The period of increased risk was concentrated primarily within the 5-week period after vaccination, although it lasted for approximately 9 or 10 weeks.
ISSN:0002-9262
1476-6256
DOI:10.1093/oxfordjournals.aje.a112795